Fulcrum forms Scientific Advisory Board to improve therapeutics development
These experts will assist and supervise the development of Fulcrum's growing therapeutics program.
“We are thrilled to bring together this distinguished group of scientific leaders on our SAB, each of whom has contributed vital discoveries that have shed light on the role of gene regulation in the development of Fragile X, FSHD and other diseases of interest,” Fulcrum President and CEO Dr. Robert Gould said. “The collective perspectives of this group form a powerhouse SAB that bring disease relevant expertise to complement our Founders Board. They will be an invaluable resource to our management team as we build a CNS franchise and a muscular dystrophy franchise composed of new medicines to transform gene regulation in disease.”
Fulcrum was formed earlier this year by a group of high-profile scientific founders to turn new genomic discoveries into medications that help regulate gene expression to restore health.
The founders of the company have extensive expertise in transcription biology.
Organizations in this story
Fulcrum Therapeutics Cambridge, MA 02139